3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Primary Myelofibrosis
13
Myeloproliferative Disorders
9
Leukemia, Myeloid, Acute
8
Thrombocythemia, Essential
6
Polycythemia Vera
6
Myelodysplastic Syndromes
5
Leukemia
5
Recurrence
3
Neoplasms
3
Lymphoma, T-Cell
3
Graft vs Host Disease
3
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma
2
Leukemia, Prolymphocytic, T-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hematologic Neoplasms
2
Uveal Melanoma
1
Thalassemia
1
Targeted Therapy
1
Prostatic Neoplasms
1
Preleukemia
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Neoplasms by Histologic Type
1
Mycosis Fungoides
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Interventions
Specimen Handling
6
Tamoxifen
4
ruxolitinib
1
pembrolizumab
1
exemestane
1
Watchful Waiting
1
Surveys and Questionnaires
1
Starch
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Radiation
1
Protons
1
Proton Therapy
1
Omacor
1
Observation
1
Methods
1
Metformin
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Laser Therapy
1
Interviews as Topic
1
Hypnosis, Anesthetic
1
Genotype
1
Educational Status
1
Early Intervention, Educational
1
Decision Support Techniques
1
Counseling
1
Cannabidiol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Carcinoma In Situ
×
ruxolitinib
×
90 days
×
Clear all
NCT02928978
2026-04-13
TBCRC042
Baylor Breast Care Center
Phase 2
Completed
84 enrolled